COMMON STOCK PURCHASE WARRANT OncBioMune Pharmaceuticals, Inc.Security Agreement • August 6th, 2019 • OncBioMune Pharmaceuticals, Inc • Pharmaceutical preparations
Contract Type FiledAugust 6th, 2019 Company IndustryTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [INSERT NAME], or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to [INSERT WARRANTS] shares of Common Stock (subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
10% original issue discount 5% Senior Convertible NOTE DUE February 3, 2020Convertible Security Agreement • August 6th, 2019 • OncBioMune Pharmaceuticals, Inc • Pharmaceutical preparations • New York
Contract Type FiledAugust 6th, 2019 Company Industry JurisdictionTHIS 10% SENIOR CONVERTIBLE NOTE is one of a series of duly authorized and validly issued 5% Senior Convertible Notes issued at a 10% original issue discount by OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”) (this note, the “Note” and, collectively with the other notes of such series, the “Notes”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 6th, 2019 • OncBioMune Pharmaceuticals, Inc • Pharmaceutical preparations • New York
Contract Type FiledAugust 6th, 2019 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of June 3, 2019, between OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).